Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0HVSBG
ADC Name	BDC-1001
Synonyms	BDC 1001; Boltbody ISAC BDC-1001 Click to Show/Hide
Organization	Bolt Biotherapeutics, Inc.
Drug Status	Phase 1/2
Indication	In total 1 Indication(s) HER2(+) solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 2
Structure
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	TORL7/8 agonist T785		Payload Info
Therapeutic Target	Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)		Target Info
Linker Name	BG based linker		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.
Puchem SID	474492463 , 476000988 , 471299319
DrugMap ID	DMJ5MPG
TTD ID	D1XI9E

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT04278144	Phase 1/2	Phase 1/2 study of BDC-1001 as a single agent and in combination with nivolumab in patients with advanced HER2-expressing solid tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Patients with advanced metastatic HER2-expressing (IHC2/3+) or amplified solid tumors. Patients had received a median of 4 prior therapies.
Administration Dosage	4 dose levels (0.15-5.00 mg/kg) every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT04278144	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2 study of BDC-1001 as a single agent and in combination with nivolumab in patients with advanced HER2-expressing solid tumors.

References

Ref 1	Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. J Clin Oncol. 2021 39:15_suppl, 2549-2549.